Key facts
- SimBioSys’s last known valuation is $39.0M (Jul 2021).
- It has raised $21.1M across 2 recorded rounds; the latest was Early Stage VC ($5.2M) in Dec 2024.
- Notable investors include Mayo Clinic, Fox Ventures, Genoa Ventures, AV8 Ventures, Calculus Venture Capital — 11 tracked in total.
- SimBioSys has filed 2 Form Ds with the SEC since 2018, most recently Jan 2025 ($5.2M sold to 13 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for SimBioSys
Funding rounds
2 roundsAbout SimBioSys
Developer of a medical platform intended to deploy computational oncology to transform decision-making and patient experience in cancer care. The company's offerings include comprehensive datasets collected during diagnosis into personalized virtual tumors through computational scenario analysis, enabling doctors to provide a better understanding of the disease and get treated accordingly.
- Sector
- Healthcare
- HQ
- Chicago, IL, United States
- Founded
- 2017
- Employees
- 30
- Website
- simbiosys.com/
- Ownership
- Privately Held (backing)
SimBioSys doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SimBioSys shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SimBioSys in its N-PORT filings yet. We sweep new filings monthly.